Hepatic Impairment Study for Lorlatinib in Cancer Patients

NCT03726333 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
1
Enrollment
INDUSTRY
Sponsor class

Stopped The study stopped due to lack of enrollment

Conditions

Interventions

Sponsor

Pfizer